

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

- 1 **Selected Articles from This Issue**

## REVIEW

- 3 **Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer**  
Rachel K. Toth and Noel A. Warfel

## SMALL MOLECULE THERAPEUTICS

- 11 **Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer**  
Balkees Abderrahman, Philipp Y. Maximov, Ramona F. Curpan, Sean W. Fanning, Jay S. Hanspal, Ping Fan, Charles E. Foulds, Yue Chen, Anna Malovannaya, Antrix Jain, Rui Xiong, Geoffrey L. Greene, Debra A. Tonetti, Gregory R.J. Thatcher, and V. Craig Jordan
- 26 **Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A**  
**AC** Peggy A. Thompson, Boreth Eam, Nathan P. Young, Sarah Fish, Joan Chen, Maria Barrera, Haleigh Howard, Eric Sung, Ana Parra, Jocelyn Staunton, Gary G. Chiang, Adina Gerson-Gurwitz, Christopher J. Wegerski, Andres Nevarez, Jeff Clarine, Samuel Sperry, Alan Xiang, Christian Nilewski, Garrick K. Packard, Theodore Michels, Chinh Tran, Paul A. Sprengeler, Justin T. Ernst, Siegfried H. Reich, and Kevin R. Webster
- 37 **TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity**  
Jamilah Abusarah, Yun Cui, Nehme El-Hachem, Abed El-Hakim El-Kadiry, Ian Hammond-Martel, Hugo Wurtele, Annie Beaudry, Noël J.-M. Raynal, Francis Robert, Jerry Pelletier, Maja Jankovic, Francois Mercier, Samaneh Kamyabiazar, Borhane Annabi, and Moutih Rafei

- 50 **Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth**  
Shauni Lien Geeraerts, Kim Rosalie Kampen, Gianmarco Rinaldi, Purvi Gupta, Mélanie Planque, Nikolaos Louros, Elien Heylen, Kaat De Cremer, Katrijn De Brucker, Stijn Vereecke, Benno Verbelen, Pieter Vermeersch, Joost Schymkowitz, Frederic Rousseau, David Cassiman, Sarah-Maria Fendt, Arnout Voet, Bruno P.A. Cammue, Karin Thevissen, and Kim De Keersmaecker

- 64 **Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition**

**AC** Tatiana Shorstova, Jie Su, Tiejun Zhao, Michael Dahabieh, Matthew Leibovitch, Mariana De Sa Tavares Russo, Daina Avizonis, Shivshankari Rajkumar, Ian R. Watson, Sonia V. del Rincón, Wilson H. Miller Jr, William D. Foulkes, and Michael Witcher

- 76 **Disruption of SND1-MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells *In Vitro* and *In Vivo***

Peng Li, Yunjiao He, Teng Chen, Kit-Ying Choy, Tsun Sing Chow, Iris L.K. Wong, Xinqing Yang, Wenqin Sun, Xiaochun Su, Tak-Hang Chan, and Larry M.C. Chow

- 85 **Targeting Dormant Ovarian Cancer Cells *In Vitro* and in an *In Vivo* Mouse Model of Platinum Resistance**

Zhiqing Huang, Eiji Kondoh, Zachary R. Visco, Tsukasa Baba, Noriomi Matsumura, Emma Dolan, Regina S. Whitaker, Ikuro Konishi, Shingo Fujii, Andrew Berchuck, and Susan K. Murphy

# TABLE OF CONTENTS

## LARGE MOLECULE THERAPEUTICS

- 96** **Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist**  
**AC** Juan Manuel García-Martínez, Shirley Wang, Cordula Weishaepfl, Andreas Wernitznig, Paolo Chetta, Catarina Pinto, Jason Ho, Darrin Dutcher, Philip N. Gorman, Rachel Kroe-Barrett, Joerg Rinnenthal, Craig Giragossian, Maria Antonietta Impagnatiello, Iñigo Tirapu, Frank Hilberg, Norbert Kraut, Mark Pearson, and Klaus Peter Kuenkele
- 109** **TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors**  
**AC** Richard J. Austin, Bryan D. Lemon, Wade H. Aaron, Manasi Barath, Patricia A. Culp, Robert B. DuBridg, Luke B. Evin, Adrié Jones, Anand Panchal, Purbasa Patnaik, Vanitha Ramakrishnan, Sony S. Rocha, Pui Seto, Kenneth Sexton, Kathryn L. Strobel, Russell Wall, Stephen Yu, Timothy Z. Yu, Che-Leung Law, Patrick A. Baeuerle, and Holger Wesche
- 121** **Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies**  
Julie Preillon, Julia Cuende, Virginie Rabolli, Lucile Garnero, Marjorie Mercier, Noémie Wald, Angela Pappalardo, Sofie Denies, Diane Jamart, Anne-Catherine Michaux, Romain Pirson, Vincent Pitard, Martine Bagot, Shruthi Prasad, Erica Houthuys, Margreet Brouwer, Reece Marillier, Florence Lambomez, João R. Marchante, Florence Nyawouame, Mathew J. Carter, Véronique Baron-Bodo, Anne Marie-Cardine, Mark Cragg, Julie Déchanet-Merville, Gregory Driessens, and Catherine Hoofd

## COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 132** **Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma**  
**AC** Javier Martín-Broto, Antonio López Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean-Yves Blay, James S. Hu, Gerard J. Oakley III, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, and Robin L. Jones
- 142** **HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia**  
Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji, and Shinya Kimura

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 150** **Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer**  
Yuchen Zhang, Michael B. Ware, Mohammad Y. Zaidi, Amanda N. Ruggieri, Brian M. Olson, Hannah Komar, Matthew R. Farren, Ganji Purnachandra Nagaraju, Chao Zhang, Zhengjia Chen, Juan M. Sarmiento, Rafi Ahmed, Shishir K. Maithel, Bassel F. El-Rayes, and Gregory B. Lesinski
- 161** **PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways**  
Shengqin Su, Gagan Chhabra, Mary A. Ndiaye, Chandra K. Singh, Ting Ye, Wei Huang, Colin N. Dewey, Vijayasaradhi Setaluri, and Nihal Ahmad
- 173** **Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity**  
Sang-In Kim, Anthony K. Park, Shyambabu Chaurasiya, Seonah Kang, Jianming Lu, Annie Yang, Venkatesh Sivanandam, Zhifang Zhang, Yanghee Woo, Saul J. Priceman, Yuman Fong, and Susanne G. Warner
- 183** **The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer**  
Brittany A. Borden, Yasmine Baca, Joanne Xiu, Fabio Tavora, Ira Winer, Benjamin A. Weinberg, Ari M. Vanderwalde, Sourat Darabi, W. Michael Korn, Andrew P. Mazar, Francis J. Giles, Lorin Crawford, Howard Safran, Wafik S. El-Deiry, and Benedito A. Carneiro
- 191** **IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases**  
Rosalie G. Hoyle, Huiqun Wang, Yana Cen, Yan Zhang, and Jiong Li

## MODELS AND TECHNOLOGIES


- 203** **Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase *In Vivo* Efficacy**  
**AC** Jose F. Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher Espelin, Neeraj Kohli, Bahar Matin, Yulius Setiady, Michael L. Miller, Thomas A. Keating, Ravi Chari, Jan Pinkas, Richard Gregory, and Greg M. Thurber
- 213** **Acknowledgement to Reviewers**

**AC** AC icon indicates AuthorChoice  
For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# TABLE OF CONTENTS

## ABOUT THE COVER

In this issue, Su, Chhabra, and colleagues demonstrate that PLK1, a mitotic regulator, and NOTCH1, a protein involved in cell fate determination, are positively correlated in melanoma and associated with patient survival. Further, combined inhibition of PLK1 and NOTCH1 was found to result in synergistic anti-proliferative effects. The cover image represents a tissue core from an in-house human melanoma tissue microarray containing multiple cases of melanomas and benign nevi. The cores were stained for S100 (green), PLK1 (red), NOTCH1 (orange), and DAPI (blue), followed by a multispectral quantitative fluorescence imaging analysis using Vectra scanner coupled with Nuance and InForm software. Read the full article on page 161.



# Molecular Cancer Therapeutics

**20 (1)**

*Mol Cancer Ther* 2021;20:1-216.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/20/1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/1>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.